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Background: Diabetic retinopathy (DR) is an important microvascular complication of diabetes with a high
concordance rate in patients with diabetes. Inflammation is supposed to participate in the development of DR.
This study aimed to investigate whether genetic variants of CRP are associated with DR.
Methods: A total of 1,018 patients with type 2 diabetes were recruited in this study. Of these patients, 618 were
diagnosed with DR, 400 were patients with diabetes for over 10 years but without DR, considered as cases and
controls for DR, respectively. Four tagging SNPs (rs2808629, rs3093077, rs1130864 and rs2808634) within CRP region
were genotyped for all the participants. Fundus photography was performed for diagnosis and classification for DR.
Results: rs2808629 was significantly associated with increased susceptibility to DR (odds ratio 1.296, 95% CI 1.076-1.561,
P = 0.006, empirical P = 0.029, for G allele). This association remained significant after adjustment for confounding
factors (odds ratio 1.261, 95% CI 1.022-1.555, P = 0.030).
Conclusions: In this study, we found CRP rs2808629 was associated with DR in the Chinese patients with type 2 diabetes.
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Diabetes mellitus, especially type 2 diabetes mellitus
(T2DM), has become a global epidemic. With the rapid
rising incidence of T2DM, diabetic complications will
certainly pose a major public health concern in the com-
ing decades. Diabetic retinopathy (DR) is a major micro-
vascular complication of diabetes and ranks as the leading
cause of blindness among working-aged adults around the
world [1]. Epidemiological studies have shown that the in-
cidence of DR parallels with diabetes duration and inten-
sive glycaemic control can delay its development [2].
However it is noteworthy that some patients with good
glycaemic control may still develop DR whereas some are
spared from DR despite poor glycaemic control. Although
the mechanisms underlie this observation remains largely* Correspondence: alfredhc@sjtu.edu.cn; wpjia@sjtu.edu.cn
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unless otherwise stated.unknown, inherited susceptibility may modulate the risk
of DR because retinopathy aggregates in families. Siblings
of patients with T2DM who have DR showed a significant
higher risk of DR compared to siblings of patients with
T2DM who have no DR [3,4]. Significant familial influence
on the severity of DR was also observed [5,6] and the risk
of DR varies among different ethnic groups [7-9]. To data,
although no locus for DR from genome-wide association
study (GWAS) has reached conventional significance cri-
teria, but a significant number of genes and genetic variants
have been proposed for DR or proliferative DR through
candidate gene approach [10,11]. Several pathways and pro-
cesses, including the renin-angiotensin system, vascular
endothelial dysfunction, tissue matrix remodeling, and
angiogenesis, have been strongly implicated in the patho-
genesis of DR, and multiple genes involved in these path-
ways have been identified for DR (e.g., AKR1B1, VEGFA,
ACE, and AGER).
C-reactive protein (CRP), a very sensitive marker of in-
flammation produced by the liver cells in response tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and angiogenesis [12,13] which have been proposed to
play an important role in the pathogenesis of DR
[14,15]. It is now well accepted that CRP is a strong pre-
dictor of future cardiovascular events [16,17]. However,
less is known about its relationship with microvascular
complications of diabetes. In this regard, some, though
not all, studies (especially prospective studies) have re-
ported that circulating CRP is associated with diabetic
nephropathy (DN) [18,19] and DR [15,20] in the last
decade, raising the possibility that the increase of CRP
may be an early event or even one of driving forces in
the development of microvascular complications of dia-
betes. Therefore, it is plausible to hypothesize that gen-
etic variants of CRP may have impact on the risk of
these complications. In the current study, we investi-




This study involved 1,018 patients with T2DM recruited
from the Shanghai Diabetes Institute Inpatient Database
of Shanghai Jiao Tong University Affiliated Sixth People’s
Hospital. All participants were unrelated patients with
T2DM meeting the 1999 WHO criteria (fasting plasma
glucose ≥ 7.0 mmol/l and/or 2 h plasma glucose ≥
11.1 mmol/l). Type 1 diabetes and mitochondrial diabetes
were excluded by clinical, immunological (individuals with
GAD and/or protein tyrosine phosphatase IA-2 antibodies
were excluded) and genetic methods (mitochondrial
tRNALeu(UUR) A3243G mutation carriers were excluded).
Of these patients, 618 were diagnosed with DR, 400 were
patients without DR, considered as cases and controls for
DR, respectively. For controls selection, patients with dia-
betes for over 10 years were chosen deliberately. This
study was approved by the institutional review board of
Shanghai Jiao Tong University Affiliated Sixth People’s
Hospital, with written informed consent obtained from
each participant.
Clinical measurement
Each participant completed a standard questionnaire for
detailed information as described previously [21]. Fundus
photography was performed according to a standardized
protocol at the Department of Ophthalmology, Shanghai
Jiao Tong University Affiliated Sixth People’s Hospital.
Both eyes of each patient were photographed with a 45-
degree 6.3-megapixel digital nonmydriatic camera (Canon
CR6-45NM, Lake Success, NY). A five-stage disease sever-
ity classification for DR was applied according to the Inter-
national Classification of Diabetic Retinopathy [22]: no
apparent retinopathy (no abnormalities), mild nonproli-
ferative diabetic retinopathy (NPDR) (microaneurysmsonly), moderate NPDR (more than just microaneurysms
but less than severe NPDR), severe NPDR (more than 20
intraretinal hemorrhages in each of 4 quadrants and/or
definite venous beading in 2 quadrants and/or prominent
intraretinal microvascular abnormalities in 1quadrant and
no signs of proliferative retinopathy), or proliferative dia-
betic retinopathy (PDR) (neovascularization and/or vitre-
ous hemorrhage and/or preretinal hemorrhage). DR grade
was evaluated for both eyes, and higher grade was re-
corded for each person. Of the 618 patients with DR in
this study, there were 395 with mild NPDR, 103 with
moderate NPDR, 84 with severe NPDR, and 36 with PDR.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by height in meters squared. Glycaemic
control was evaluated by measuring glycated haemoglobin
(HbA1c) levels. Data of blood pressures and lipid profiles
were also collected for each participant. Hypertension was
defined as systolic blood pressure ≥ 140 mmHg and/or
diastolic blood pressure ≥ 90 mmHg.
Single nucleotide polymorphisms (SNPs) selection,
genotyping and quality control
In this study, we selected four tagging SNPs (rs2808629,
rs3093077, rs1130864 and rs2808634) that spanned
11 kb in the upstream and 6 kb in the downstream region
of CRP, according to HapMap phase III (release 28) Han
Chinese database with a threshold of r2 ≥ 0.8. We could
tag 95% SNPs (21 out of 22 SNPs) with a minor allele
frequency (MAF) > 0.01 within CRP region. All genotyp-
ing was done using the primer extension of multiplex
products with detecting by matrix-assisted laser desorp-
tion ionization-time of flight mass spectroscopy using a
MassARRAY Compact Analyzer (Sequenom, San Diego,
CA, USA). The genotyping data underwent a series of
quality control checks and cleaned data were used in
further statistical analysis. The call rates for rs2808629,
rs3093077, rs1130864 and rs2808634 were 97.0%, 95.9%,
98.3% and 96.9%, respectively. The concordance rates
based on 100 duplicates were over 99% for all these
SNPs. Thirty-seven individuals were excluded from the
sample call rate checks. The Hardy-Weinberg equilib-
rium test was performed before the association analysis,
and all the four SNPs were in accordance with Hardy-
Weinberg equilibrium (P = 0.68 for rs2808629, P = 0.74
for rs3093077, P = 0.34 for rs1130864 and P = 0.47 for
rs2808634, respectively).
Statistical analysis
The allelic frequencies between the patients with or with-
out DR were compared by χ2 test, and odds ratios with
95% confidence intervals (CIs) were presented. Genotype
distributions between patients with or without DR were
compared using multiple logistic regressions under an
additive model with adjustment for confounding factors.
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were analyzed by trend analysis. All these analyses were
performed using SAS 9.3 (SAS institute, Cary, NC, USA)
unless specified otherwise. A two-tailed P value < 0.05 was
considered statistically significant.
On the basis of the previously reported effect size of
genetic loci for DR (~1.40) [10], our samples had > 90%
power to detect an effect SNP with MAF of 0.3 and >
80% power to detect an effect SNP with MAF of 0.2 at a
level of significance of 0.05.
Results
The clinical characteristics of the subjects passed geno-
type quality control were shown in Table 1. Compared
with patients without DR, patients with DR were diag-
nosed with diabetes at earlier age and had higher HbA1c
levels and higher prevalence of hypertension and dia-
betic nephropathy. Besides, as patients without DR with
diabetes for over 10 years were selected in our study,
they were older and had longer duration of diabetes
compared with patients with DR.
We firstly analyzed the association between these SNPs
and the risk of DR. As shown in Table 2, rs2808629 was
nominally associated with increased susceptibility to DR
(odds ratio 1.296, 95% CI 1.076-1.561, P = 0.006, for G al-
lele). This association remained significant after adjusting
for confounding factors, including HbA1c levels, duration
of diabetes, systolic and diastolic blood pressure, BMI and
sex (odds ratio 1.261, 95% CI 1.022-1.555, P = 0.030), as
well as adjusting for multiple comparisons (empirical P =
0.029). The other SNPs did not show any association with
DR. Further, we tried to examine the effect of rs2808629
on the disease severity of DR. Of the 593 DR patients,
there were 379 patients with mild NPDR, 98 with moder-
ate NPDR, 80 with severe NPDR and 36 with PDR. How-




Age (years) 62.48 ± 10.79
BMI (kg/m2) 24.12 ± 3.65
Age at diagnosis of diabetes (years) 51.70 ± 10.60
Duration of diabetes (years) 10.00(5.00,15.00)
HbA1c (%) 9.16 ± 2. 17
Systolic blood pressure (mmHg) 138.66 ± 18.90
Diastolic blood pressure (mmHg) 81.39 ± 9.55
Subjects with hypertension [n (%)] 335(56.5%)
Subjects with nephropathy [n (%)] 232(39.1%)
Data are n, mean ± SD or median (interquartile range). BMI, body mass index.
25 patients with DR and 12 patients without DR were excluded due to sample callseverity was observed (P = 0.387 for trend analysis). The
distributions of these four SNPs among patients with dif-
ferent levels of DR were shown in Table 3. In addition,
rs2808629 was genotyped among 438 subjects with nor-
mal glucose regulation. The distribution of this SNP was
similar to those reported in other studies of Asian popula-
tions in the HapMap database (G allele frequency 0.453 vs
0.419/0.297/0.537), indicating that there was no technical
error in this study.
Discussion
In the present study, we investigated the association of
CRP variants with DR in Chinese patients with T2DM.
It’s the first time to our knowledge to investigate the asso-
ciation between CRP variants with DR. Our results re-
vealed that rs2808629 was significantly associated with the
risk of DR in Chinese patients with T2DM. This associ-
ation remained significant after adjusting for multiple com-
parisons. Moreover, the correlation of rs2808629 with DR
stayed significant after adjusting for confounding factors,
including duration of diabetes, HbA1c, blood pressure,
BMI and sex, implying that this SNP is an independent
genetic factor for susceptibility to DR. It has been reported
in several studies that CRP genetic variants were associ-
ated with serum CRP levels [23-28]. rs2808629 was identi-
fied to be associated with serum CRP levels in a previous
genome-wide association study [23]. Therefore, it is plaus-
ible that the effect of rs2808629 on susceptibility to DR is
because of its influence on serum CRP levels. However,
further studies are needed for confirmation.
As an acute phase reactant, CRP production increases in
response to a variety of systemic events such as infection,
trauma, or autoimmune inflammatory diseases. Among
other systemic inflammatory mediators, CRP has been
widely accepted as a potent risk indicator, independently
predicting future cardiovascular events in the last decadesPatients without retinopathy P value
(n = 388)
154/234 0.010
67.37 ± 9.62 <0.0001
24.02 ± 3.36 0.861
53.39 ± 9.87 0.014
12.00(10.00,16.00) <0.0001
8.70 ± 2.11 0.0003
135.98 ± 17.83 0.014




























rs2808629 1:159707006 +5283 A/G G 0.452 171/297/115 0.389 141/180/57 1.296(1.076,1.561) 0.006(0.029) 1.261(1.022,1.555) 0.030
rs3093077 1:159709846 +2443 T/G G 0.183 390/179/18 0.163 271/106/10 1.153(0.906,1.468) 0.248(0.612) 1.194(0.906,1.574) 0.209
rs1130864 1:159713301 3’ UTR C/T T 0.058 520/62/3 0.045 352/33/1 1.299(0.855,1.974) 0.219(0.667) 1.250(0.794,1.968) 0.335
rs2808634 1:159722783 −8194 C/T T 0.160 420/155/17 0.151 281/97/10 1.070(0.833,1.375) 0.597(0.968) 1.056(0.804,1.386) 0.697
P values < 0.05 are shown in bold.
The additive model was used in the association analysis between genotype and DR.
*position of SNP with reference to CRP.
#11, major allele homozygotes; 12, heterozygotes; 2 2, minor allele homozygotes.
§adjusted for duration of diabetes, HbA1c, systolic blood pressure, diastolic blood pressure, body mass index and sex.
Empirical P values are based on 10,000 permutations.













Table 3 CRP SNPs distributions among patients with different severities of DR
SNP Mild NPDR Moderate NPDR Severe NPDR PDR

















rs2808629 0.465 110/180/84 0.463 25/52/18 0.405 25/44/10 0.386 11/21/3
rs3093077 0.196 242/122/13 0.168 67/24/4 0.163 55/24/1 0.129 26/9/0
rs1130864 0.053 339/34/3 0.072 83/14/0 0.058 69/9/0 0.074 29/5/0
rs2808634 0.166 263/106/10 0.168 69/25/4 0.127 61/16/2 0.139 27/8/1
#11, major allele homozygotes; 12, heterozygotes; 22, minor allele homozygotes.
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nized link between chronic inflammation and microvascu-
lar complications [15,32], the relationship between CRP
and DR has been investigated in some studies. However,
results from limited studies on possible association of CRP
with DR are inconsistent. In the Hoorn study [15], a large
population-based cohort study of 625 adults, higher CRP
was associated with the prevalence of any DR. Another
prospective study of inflammatory biomarkers and risk of
DR in the Diabetes Control and Complications Trial also
indicated that after adjusting for known risk factors, in-
creasing quintiles of baseline high-sensitivity CRP (hsCRP)
level may be associated with higher risks of incident clinic-
ally significant macular edema and the development of
macular hard exudates [33]. However, report from the
Wisconsin Epidemiologic Study of Diabetic Retinopathy
(WESDR) [34], a longitudinal population based study of
persons with type 1 diabetes, did not find any association
between CRP and DR. Similar results were reported by the
Multi-ethnic Study of Atherosclerosis (MESA) [35]. Be-
sides, Lim et al. [36] reported that patients with higher
levels of CRP were less likely to have DR in the Singapore
Malay Eye Study (SiMES), a cross-sectional study on 718
persons with diabetes. Nevertheless, emerging evidence
supports CRP as an active participant instead of a mere
bystander in the pathogenesis of DR. CRP could inhibit
endothelium-dependent nitric oxide-mediated dilation in
retinal arterioles, thus potentially facilitating the develop-
ment of retinal vascular diseases [37]. Besides, CRP could
stimulate leucocyte-endothelium interactions [38], de-
crease endothelial nitric oxide [39], and impair the num-
ber and function of endothelial progenitor cells [40],
thereby promoting endothelial dysfunction, which is an-
other important mediator in the development of diabetic
microvascular complications [15]. Taken together, these
findings imply that genetic variants of CRP may exert sig-
nificant effects on DR. And our study found a common
variant of CRP, rs2808629, was significantly associated
with DR in the Chinese patients with T2DM.
Some limitations should be noted in our study. Firstly, al-
though the association of rs2808629 with DR remained sig-
nificant after adjusting for multiple comparisons (empiricalP = 0.029), we still cannot fully exclude the possibility that
the association detected was a false positive. But consider-
ing the power of our study samples and the effect of this
SNP, the possibility of a false positive is limited. Secondly,
rs2808629 locates in the downstream of CRP, and we sup-
pose that it may participate in the susceptibility to DR
through its effects on regulating CRP expression or it
may be just a genetic marker in linkage disequilibrium
with the causal variant(s). However, further studies are
needed to reveal the underlying mechanism. Thirdly, al-
though we found association of CRP variant with DR in
Chinese patients with T2DM, whether this effect is re-
stricted to T2DM is still unknown and needs to be in-
vestigated in studies among patients with type 1
diabetes and other ethnic groups.Conclusions
In summary, we found that CRP rs2808629 was associ-
ated with DR in Chinese patients with T2DM. This study
discover the association of CRP variant with DR for the
first time, although the mechanism underlying the geno-
type–phenotype association is unknown, it provides a
hypothesis for future researches. Further studies are
needed to replicate this finding in other populations and
translate the common variant association signal into bio-
logical mechanisms of disease causation.
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